PBT2 News, page-18

Acknowledgments

This work was supported by the National Health and Medical Research Council (NHMRC) Project Grants 1080784 and 1140554 to C.A.M. and M.J.M., 1176180 and 1194130 to M.J.W., 1071659 to M.J.W. and M.V.I., and 1122582 to C.A.M. and the Australian Research Council (ARC) Discovery Project Grant DP170102102 to C.A.M. This work was also supported by the National Institutes of Health grants (1U01AI124302 and 1RO1AI110618) to J.W.R. S.L.N. is an NHMRC Early Career Research Fellow (1142695) and C.A.M. and M.J.M. are ARC Future Fellows (FT170100006 and FT180100397, respectively). Part of this study was carried out using the MX2 beamline at the Australian Synchrotron, which is part of Australian Nuclear Science and Technology Organization (ANSTO) and made use of the Australian Cancer Research Foundation (ACRF) Detector. We thank the beamline staff for their enthusiastic and professional support, Prof. Jan-Willem Veening (University of Lausanne) for provision of the hlpA fluorescent construct and Prof. Michael Caparon (Washington University) for the pABG5-3 mini plasmid.

Nothing to do with ATH I am pretty sure.